All In Biotech

Drug Trial Radar · NCT07412470

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

526

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Aug 15, 2029

Study completion Aug 15, 2033

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.

Conditions

  • Kidney Transplant Rejection

Interventions

  • FrexalimabDrug

    Pharmaceutical form:Solution for injection-Route of administration:IV

  • FrexalimabDrug

    Pharmaceutical form:Solution for injection-Route of administration:SC

  • TacrolimusDrug

    Pharmaceutical form:Capsule-Route of administration:Oral

  • rabbit anti-thymocyte globulinDrug

    Pharmaceutical form:Solution for injection-Route of administration:IV

  • mycophenolate mofetilDrug

    Pharmaceutical form:Tablet or capsule-Route of administration:Oral

  • mycophenolate sodiumDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • methylprednisoloneDrug

    Pharmaceutical form:Solution for injection-Route of administration:IV

  • prednisoneDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantationTime frame: by 1 year

Locations

73 sites in 18 countries. Site status is shown where the registry gives one.

  • University of California San Francisco - Parnassus Heights- Site Number : 8400001

    San Francisco, California · Recruiting

  • Emory University Hospital- Site Number : 8400002

    Atlanta, Georgia · Recruiting

  • Edward Hines, Jr. Veterans Affairs Hospital- Site Number : 8400010

    Hines, Illinois · Recruiting

  • University of Kansas Medical Center- Site Number : 8400044

    Kansas City, Kansas · Recruiting

  • University of Maryland School of Medicine - Baltimore- Site Number : 8400045

    Baltimore, Maryland · Recruiting

  • Brigham & Women's Hospital- Site Number : 8400049

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System - Ann Arbor- Site Number : 8400022

    Ann Arbor, Michigan · Recruiting

  • The Mount Sinai Hospital- Site Number : 8400027

    New York, New York · Recruiting

  • Columbia University Irving Medical Center- Site Number : 8400007

    New York, New York · Recruiting

  • Weill Cornell Medical College- Site Number : 8400005

    New York, New York · Recruiting

  • Montefiore Medical Center - Moses Campus- Site Number : 8400006

    The Bronx, New York · Recruiting

  • The Ohio State University- Site Number : 8400025

    Columbus, Ohio · Recruiting

  • VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400004

    Richmond, Virginia · Recruiting

  • University of Washington Medical Center- Site Number : 8400035

    Seattle, Washington · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320001

    Corrientes, Argentina · Recruiting

  • Investigational Site Number : 0360003

    Sydney, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360002

    Adelaide, South Australia, Australia · Recruiting

  • Investigational Site Number : 0360004

    Clayton, Victoria, Australia · Recruiting

  • Investigational Site Number : 0360001

    Parkville, Victoria, Australia · Recruiting

  • Investigational Site Number : 0560002

    Brussels, Belgium · Recruiting

  • Investigational Site Number : 0560001

    Leuven, Belgium · Recruiting

  • Hospital do Rim e Hipertensão- Site Number : 0760001

    São Paulo, Brazil · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760006

    São Paulo, Brazil · Recruiting

  • Hospital Geral de Fortaleza - HGF- Site Number : 0760007

    Fortaleza, Ceará, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760004

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Investigational Site Number : 1520005

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1560018

    Beijing, China · Recruiting

  • Investigational Site Number : 1560003

    Chengdu, China · Recruiting

  • Investigational Site Number : 1560007

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560020

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560002

    Hangzhou, China · Recruiting

  • Investigational Site Number : 1560012

    Jinan, China · Recruiting

  • Investigational Site Number : 1560017

    Nanchang, China · Recruiting

  • Investigational Site Number : 1560008

    Nanning, China · Recruiting

  • Investigational Site Number : 1560016

    Shanghai, China · Recruiting

  • Investigational Site Number : 1560001

    Shanghai, China · Recruiting

  • Investigational Site Number : 1560011

    Tianjin, China · Recruiting

  • Investigational Site Number : 1560006

    Wuhan, China · Recruiting

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.